No connection

Search Results

ABBV vs AKBA

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
AKBA
Akebia Therapeutics, Inc.
BEARISH
Price
$1.46
Market Cap
$391.1M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABBV
163.63
AKBA
--
Forward P/E
ABBV
15.42
AKBA
-15.37
P/B Ratio
ABBV
-146.66
AKBA
11.87
P/S Ratio
ABBV
6.5
AKBA
1.66
EV/EBITDA
ABBV
15.27
AKBA
14.85

Profitability

Gross Margin
ABBV
71.46%
AKBA
82.92%
Operating Margin
ABBV
35.5%
AKBA
-10.5%
Profit Margin
ABBV
4.0%
AKBA
-2.26%
ROE
ABBV
137.96%
AKBA
--
ROA
ABBV
9.59%
AKBA
5.44%

Growth

Revenue Growth
ABBV
9.1%
AKBA
23.9%
Earnings Growth
ABBV
-88.7%
AKBA
--

Financial Health

Debt/Equity
ABBV
--
AKBA
6.1
Current Ratio
ABBV
0.72
AKBA
1.55
Quick Ratio
ABBV
0.47
AKBA
1.42

Dividends

Dividend Yield
ABBV
3.05%
AKBA
--
Payout Ratio
ABBV
490.15%
AKBA
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
AKBA BEARISH

AKBA's Advanced Deterministic Scorecard reveals significant financial distress signals: a Piotroski F-Score of 2/9 indicates weak operational and financial health, while the absence of an Altman Z-Score raises bankruptcy risk concerns. Despite strong revenue growth (23.9% YoY) and a high gross margin (82.92%), the company operates at a net loss with negative profit and operating margins, and carries a dangerously high debt/equity ratio of 6.10. Insider selling activity totaling $0.90M over six months, including large sales by executives and the CEO, reinforces bearish sentiment. The stock trades at a premium valuation (Price/Sales: 1.66, Price/Book: 11.87) despite negative earnings and no intrinsic value support, making it vulnerable to downside pressure.

Strengths
Strong revenue growth of 23.9% YoY
High gross margin of 82.92% indicates pricing power or low production costs
Positive recent quarterly earnings surprises (average +53.7% over last 4 quarters)
Risks
Piotroski F-Score of 2/9 indicates severe financial and operational weakness
Debt/Equity ratio of 6.10 is extremely high, signaling financial leverage risk
Negative net profit margin (-2.26%) and operating margin (-10.50%) despite revenue growth

Compare Another Pair

ABBV vs AKBA: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Akebia Therapeutics, Inc. (AKBA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile